{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:46:04Z","timestamp":1790318764674,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11523-021-00827-0","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T11:02:41Z","timestamp":1628161361000},"page":"675-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Isatuximab: A Review of Its Use in Multiple Myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"827_CR1","first-page":"470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Artzebl Int. 2016;113:470\u20136.","journal-title":"Dtsch Artzebl Int."},{"issue":"9","key":"827_CR2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma; a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"issue":"1","key":"827_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313.","journal-title":"Haematologica"},{"issue":"20","key":"827_CR4","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076\u201384.","journal-title":"Blood"},{"key":"827_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR. Multiple myeloma: available therapies and causes of drug resistance. Cancers. 2020;12:407.","journal-title":"Cancers"},{"key":"827_CR6","unstructured":"Rajkumar SV. Multiple myeloma: selection of initial chemotherapy for symptomatic disease. UpToDate. https:\/\/www.uptodate.com\/home. Accessed 18 Mar 2021."},{"key":"827_CR7","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.3390\/ijms19123924","volume":"19","author":"HN Abramson","year":"2018","unstructured":"Abramson HN. Monoclonal antibodies for the treatment of multiple myeloma: an update. Int J Mol Sci. 2018;19:3924.","journal-title":"Int J Mol Sci"},{"key":"827_CR8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkimar","year":"2020","unstructured":"Rajkimar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Haematol. 2020;95:548\u201367.","journal-title":"Am J Haematol."},{"key":"827_CR9","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, Al Hamed RA, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33:2343\u201357.","journal-title":"Leukemia"},{"key":"827_CR10","first-page":"1","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1\u201313.","journal-title":"Palliat Care Soc Pract."},{"key":"827_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2011","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2011;26:149\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"827_CR12","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.beha.2020.101143","volume":"33","author":"K Wudhikarna","year":"2020","unstructured":"Wudhikarna K, Wills B, Lesokhind AM. Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol. 2020;33(1):101143.","journal-title":"Best Pract Res Clin Haematol"},{"key":"827_CR13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252\u201362.","journal-title":"Leukemia"},{"key":"827_CR14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ, Usmani SZ. CD38 Antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.","journal-title":"Front Immunol"},{"key":"827_CR15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","volume":"12","author":"PG Richardson","year":"2020","unstructured":"Richardson PG. Isatuximab for the treatment of relapsed\/refractory multiple myeloma. Expert Opin Biol Ther. 2020;12:1395\u2013404.","journal-title":"Expert Opin Biol Ther"},{"key":"827_CR16","unstructured":"Sanofi-Aventis. SARCLISA (isatuximab): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu. Accessed 22 Apr 2021."},{"key":"827_CR17","unstructured":"Sanofi-Aventis. SARCLISA\u00ae (isatuximab-irfc): US prescribing information. 2021. https:\/\/www.fda.gov\/drugs. Accessed 22 Apr 2021."},{"key":"827_CR18","unstructured":"Sanofi Co., Ltd. Sarclisa intravenous infusion 100mg\/Sarclisa intravenous infusion 500mg: Japanese prescribing information. 2021. https:\/\/www.pmda.go.jp. Accessed 22 Apr 2021."},{"issue":"17","key":"827_CR19","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574\u201383.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"827_CR20","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","volume":"25","author":"L Moreno","year":"2019","unstructured":"Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176\u201387.","journal-title":"Clin Cancer Res"},{"issue":"1771","key":"827_CR21","first-page":"1","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Song Z, Wang A, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11(1771):1\u201319.","journal-title":"Front Immunol"},{"issue":"12","key":"827_CR22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/cells8121522","volume":"8","author":"TG Martin","year":"2019","unstructured":"Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):1522.","journal-title":"Cells"},{"issue":"2","key":"827_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399\u2013408.","journal-title":"Leukemia"},{"issue":"15","key":"827_CR24","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290\u2013300.","journal-title":"Clin Cancer Res"},{"key":"827_CR25","unstructured":"European Medicines Agency. Sarclisa (isatuximab): assessment report. https:\/\/www.ema.europa.eu. Accessed 28 Jan 2021."},{"issue":"68","key":"827_CR26","doi-asserted-by":"crossref","first-page":"112166","DOI":"10.18632\/oncotarget.22992","volume":"8","author":"Y-T Tai","year":"2017","unstructured":"Tai Y-T, Anderson KC. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017;8(68):112166\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"827_CR27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41375-019-0536-3","volume":"34","author":"D Atanackovic","year":"2020","unstructured":"Atanackovic D, Yousef S, Shorter C, et al. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia. 2020;34(1):317\u201321.","journal-title":"Leukemia"},{"issue":"10214","key":"827_CR28","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107.","journal-title":"Lancet"},{"issue":"10292","key":"827_CR29","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"key":"827_CR30","doi-asserted-by":"crossref","unstructured":"Finn G, Mace S, Campana F, et al. Evaluating isatuximab interference with monoclonal protein detection by immuno-capture and liquid chromatography coupled to high resolution mass spectrometry in the pivotal phase 3 multiple myeloma trial, ICARIA-MM [abstract no. 3143]. In: American Society of Hematology 61st Annual Meeting. 2019.","DOI":"10.1182\/blood-2019-129963"},{"issue":"Suppl 1","key":"827_CR31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-137681","volume":"136","author":"T Martin","year":"2020","unstructured":"Martin T, Mikhael J, Hajek R, et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: Ikema interim analysis. Blood. 2020;136(Suppl 1):7\u20138.","journal-title":"Blood"},{"issue":"2","key":"827_CR32","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2217\/fon-2019-0431","volume":"16","author":"P Moreau","year":"2020","unstructured":"Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA phase III study design. Future Oncol. 2020;16(2):4347\u201358.","journal-title":"Future Oncol"},{"key":"827_CR33","unstructured":"US FDA Center for Drug Evaluation and Research. SARCLISA\u00ae (isatuximab-irfc): multi-discipline review. https:\/\/www.fda.gov\/drugs. Accessed 11 Mar 2021."},{"issue":"11","key":"827_CR34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/psp4.12561","volume":"9","author":"JB Fau","year":"2020","unstructured":"Fau JB, El-Cheikh R, Brillac C, et al. Drug-disease interaction and time-dependent population pharmacokinetics of isatuximab in relapsed\/refractory multiple myeloma patients. CPT Pharmacomet Syst Pharmacol. 2020;9(11):649\u201358.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"2","key":"827_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","volume":"134","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Blood. 2019;134(2):123\u201333.","journal-title":"Blood"},{"issue":"Suppl 15","key":"827_CR36","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2021.39.15_suppl.8017","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Perrot A, San-Miguel JF, et al. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM) [abstract no. 8017]. J Clin Oncol. 2021;39(Suppl 15):8017.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"827_CR37","first-page":"446","volume":"4","author":"M Beksac","year":"2020","unstructured":"Beksac M, Richardson PG, Unal A, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIAf-MM subgroup analysis [abstract no. EP978]. HemaSphere. 2020;4(Suppl 1):446.","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"827_CR38","first-page":"473","volume":"4","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Campana F, Bury DP, et al. Health-related quality of life in heavily pretreated and renally impaired patients with relapsed\/refractory multiple myeloma receiving isatuximab plus pomalidomide and dexamethasone: ICARIA-MM study [abstract no. EP1028]. HemaSphere. 2020;4(Suppl 1):473\u20134.","journal-title":"HemaSphere."},{"key":"827_CR39","doi-asserted-by":"crossref","unstructured":"Schjesvold F, Bringhen S, Richardson P, et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed\/refractory multiple myeloma: Icaria-MM subgroup analysis [abstract no. 1411]. In: American Society of Hematology 62nd Annual Meeting. 2020.","DOI":"10.1002\/ajh.26319"},{"issue":"Suppl 1","key":"827_CR40","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2019-128220","volume":"134","author":"K Houghton","year":"2019","unstructured":"Houghton K, Dimopoulos MA, Lin P, et al. Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: ICARIA-MM study. Blood. 2019;134(Suppl 1):1850.","journal-title":"Blood"},{"key":"827_CR41","doi-asserted-by":"crossref","first-page":"106576","DOI":"10.1016\/j.leukres.2021.106576","volume":"104","author":"S Bringhen","year":"2021","unstructured":"Bringhen S, Pour L, Vorobyev V, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021;104:106576.","journal-title":"Leuk Res"},{"issue":"1","key":"827_CR42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","volume":"194","author":"SJ Harrison","year":"2021","unstructured":"Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120\u201331.","journal-title":"Br J Haematol"},{"key":"827_CR43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","volume":"35","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021;35:562\u201372.","journal-title":"Leukemia"},{"issue":"15 Suppl","key":"827_CR44","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2018.36.15_suppl.8014","volume":"36","author":"A Chari","year":"2018","unstructured":"Chari A, Richter JR, Shah N, et al. Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM) [abstract no. 8014]. J Clin Oncol. 2018;36(15 Suppl):8014.","journal-title":"J Clin Oncol"},{"key":"827_CR45","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (Ikema): interim analysis of a phase 3, randomized, open-label study [abstract no. LB2603 plus oral presentation]. In: European Haematology Association 25th Congress. 2020.","DOI":"10.2217\/fon-2019-0431"},{"issue":"3 Suppl","key":"827_CR46","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S2666-6367(21)00092-0","volume":"27","author":"TG Martin","year":"2021","unstructured":"Martin TG, Capra M, Mohty M, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients who previously underwent transplantation: Ikema subgroup analysis [abstract no. 66]. Transpl Cell Ther. 2021;27(3 Suppl):S65.","journal-title":"Transpl Cell Ther."},{"issue":"Suppl 1","key":"827_CR47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136415","volume":"136","author":"M Capra","year":"2020","unstructured":"Capra M, Martin T, Moreau P, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: Ikema subgroup analysis [abstract]. Blood. 2020;136(Suppl 1):46\u20137.","journal-title":"Blood"},{"issue":"Suppl 15","key":"827_CR48","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1200\/JCO.2021.39.15_suppl.8026","volume":"39","author":"T Facon","year":"2021","unstructured":"Facon T, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis [abstract no. 8026]. J Clin Oncol. 2021;39(Suppl 15):8026.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"827_CR49","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1200\/JCO.2021.39.15_suppl.8042","volume":"39","author":"I Spicka","year":"2021","unstructured":"Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis [abstract no. 8042]. J Clin Oncol. 2021;39(Suppl 15):8042.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"827_CR50","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2019-129840","volume":"134","author":"C Hulin","year":"2019","unstructured":"Hulin C, Richardson PG, Attal M, et al. Depth of response and response kinetics in the ICARIA-MM study of isatuximab with pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma [abstract no. 3185]. Blood. 2019;134(Suppl 1):3185.","journal-title":"Blood"},{"issue":"3","key":"827_CR51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"key":"827_CR52","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 7. 2021. Multiple myeloma. https:\/\/www.nccn.org\/. Accessed 6 Jul 2021."},{"key":"827_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01262-w","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Karanes C, Bensinger WI, et al. Final results of a phase 1b study of isatuximab short-duration fixedvolume infusion combination therapy for relapsed\/refractory multiple myeloma. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01262-w.","journal-title":"Leukemia"},{"issue":"8","key":"827_CR54","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130(8):974\u201381.","journal-title":"Blood"},{"key":"827_CR55","unstructured":"Janssen-Cilag International NV. Darzalex (daratumumab): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu. Accessed 22 Apr 2021."},{"key":"827_CR56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","volume":"11","author":"J Mikhael","year":"2021","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11:89.","journal-title":"Blood Cancer J"},{"key":"827_CR57","doi-asserted-by":"crossref","unstructured":"Becnel M, Horowitz S, Thomas SK, et al. Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed\/refractory multiple myeloma [abstract no. 1371]. In: American Society of Hematology 62nd Annual Meeting. 2020.","DOI":"10.1182\/blood-2020-140526"},{"key":"827_CR58","doi-asserted-by":"crossref","unstructured":"Alrawashdh N, Almutairi A, McBride A, et al. Economic evaluation of daratumumab and pomalidomide and dexamethasone versus isatuximab and pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma [abstract no. 3419]. In: American Society of Hematology 62nd Annual Meeting. 2020.","DOI":"10.1182\/blood-2020-136348"},{"issue":"Suppl 15","key":"827_CR59","doi-asserted-by":"crossref","first-page":"e20010","DOI":"10.1200\/JCO.2021.39.15_suppl.e20010","volume":"39","author":"N Alrawashdh","year":"2021","unstructured":"Alrawashdh N, Choi B, Obeng-Kusi M, et al. Economic evaluation of 6 and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM) [abstract no. e20010]. J Clin Oncol. 2021;39(Suppl 15):e20010.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s11523-021-00846-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00827-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T16:57:23Z","timestamp":1673024243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00827-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00827-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-021-00846-x","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"6 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"video ESM update","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-021-00846-x","URL":"https:\/\/doi.org\/10.1007\/s11523-021-00846-x","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J. E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}